The global injectable drug delivery devices market size is calculated at USD 519 billion in 2024 and is predicted to reach around USD 1,217 billion by 2034, expanding at a CAGR of 8.9% from 2024 to 2034.
The injectable drug delivery market can be stated as the robust portfolio of healthcare products including injectable insulin pens, smart wearable devices, and self-injectors to deliver medications or prescribed drugs to the patients. The production of prefilled syringes, injectables, auto-injectors, and pen-injectors is increased by pharmaceutical companies. The emerging need for these medical devices to treat chronic and age-related conditions such as hypertension, diabetes, and arthritis propels the market’s growth. The upscaling demand for needle-free injection drug delivery products, reusable, autoinjectors, and disposable prefilled injection pens upsurges the growth of this market.
Moreover, the strategic industrial collaborations in China, the rising incidence of STDs in Brazil, Industry-academia cooperation in India, high rates of obesity in the UK, and efforts of Japan to make drug delivery injectable for Alzheimer’s disease boost the expansion of the injectable drug delivery market. Pfizer Inc., Novartis AG, GlaxoSmithKline Plc, Sanofi SA, Novo Nordisk A/S, etc. are the major contributing companies to the development of innovative injectable drug delivery products in the market. The extensive use of these products in the treatments of anaphylaxis, diabetes, cardiovascular diseases, multiple sclerosis, rheumatoid arthritis, and cancer highlights their excellent features and applications in healthcare.
Published by Kesiya Chacko
